Thus, we first overexpressed (Fig. 3E and F) and silenced IGF2BP2 in breast cancer cells (Fig. 3G and H), and si-IGF2BP2-#3 with the best inhibitory effect was selected for the follow-up experiments. This evidence concerns the gene IGF2BP2 and breast carcinoma.